Supernus Pharmaceuticals, Inc.

NasdaqGM:SUPN Voorraadrapport

Marktkapitalisatie: US$2.8b

Supernus Pharmaceuticals Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Supernus Pharmaceuticals is gedaald met een gemiddeld jaarlijks percentage van -34.8%, terwijl de winst van de Pharmaceuticals -industrie jaarlijks groeide met 8.7%. De inkomsten zijn groeide met een gemiddeld percentage van 4.1% per jaar.

Belangrijke informatie

-34.79%

Groei van de winst

-35.77%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie5.95%
Inkomstengroei4.13%
Rendement op eigen vermogen-3.63%
Nettomarge-5.36%
Volgende winstupdate05 May 2026

Recente prestatie-updates uit het verleden

Shareholders Can Be Confident That Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings Are High Quality

May 13
Shareholders Can Be Confident That Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings Are High Quality

Recent updates

SUPN: Resolved Supply Constraints Will Support Future Repricing Potential

Analysts have lifted their price target on Supernus Pharmaceuticals by $5 to $65, citing refreshed models after Q4 results and improved visibility on Onapgo supply as production ramps up with the current supplier and a second source expected in 2027. Analyst Commentary Bullish Takeaways Bullish analysts view the $65 price target, up from $60, as reflecting refreshed forecasts after the latest Q4 update.

SUPN: Resolved Supply Constraints And Dual Sourcing Plans Will Support Future Repricing

Narrative Update: Supernus Pharmaceuticals Analyst Price Target Shift Analysts have lifted their price target on Supernus Pharmaceuticals to $65 from $60, citing updated models after Q4 results and expectations that Onapgo supply constraints are now addressed with increased production capacity and a planned second supplier in 2027. Analyst Commentary Analysts see the updated price target as a reflection of fresh Q4 inputs and improved visibility on Onapgo supply.

SUPN: Resolved Supply Constraints Will Support Repricing Through Improved Execution

Analysts have lifted their price target on Supernus Pharmaceuticals to $65 from $60, citing updated models after Q4 results and expectations that Onapgo supply constraints are easing with increased production capacity and an additional supplier planned for 2027. Analyst Commentary Bullish Takeaways Bullish analysts see the higher US$65 price target as a reflection of updated models that better align with recent Q4 information and current expectations for the business.

SUPN: Supply Resolution And Refined P/E Assumptions Will Support Repricing

Analysts have increased their price target on Supernus Pharmaceuticals to $65 from $60, citing updated models following Q4 results and expectations that Onapgo supply constraints are now resolved with expanded production capacity. Analyst Commentary Bullish Takeaways Bullish analysts see the higher US$65 price target as a reflection of updated Q4 assumptions that support their view of improved execution and earnings potential.

SUPN: Stable Fair Value And Refined P/E Assumptions Will Support Repricing

Analysts modestly adjusted their $61.33 price target on Supernus Pharmaceuticals as they updated their assumptions around revenue growth, profit margin, and future P/E. This reflects a more finely tuned view of the company’s earnings power and valuation risk.

SUPN: Steady Fair Value And P/E Outlook Will Support Bullish Repricing

Analysts have kept their price target for Supernus Pharmaceuticals broadly steady, citing only modest tweaks to underlying assumptions such as a slightly higher discount rate, minor adjustments to expected revenue growth and profit margin, and a largely unchanged future P/E outlook. Valuation Changes Fair Value Estimate remains unchanged at 61.33.

Supernus: Outlook For 2026 Positive, Upholding Buy Rating

Feb 01

SUPN: Higher 2025 Revenue Guidance Will Support Expanded Future Earnings Multiple

Analysts have adjusted their price target on Supernus Pharmaceuticals to US$61.33 per share, reflecting updated assumptions around discount rate, revenue growth, profit margin, and future P/E that remain broadly in line with prior estimates. What's in the News Supernus Pharmaceuticals raised its 2025 total revenue guidance to a range of US$685 million to US$705 million, including approximately US$75 million to US$85 million from Trokendi XR and Oxtellar XR (Key Developments).

SUPN: Higher 2025 Revenue Guidance Will Support Expanded Future Earnings Multiple

Analysts have inched their price target on Supernus Pharmaceuticals higher by about $0.83, citing updated assumptions that include a modest adjustment to fair value, slightly different revenue growth and profit margin expectations, and a higher future P/E multiple. What's in the News Supernus Pharmaceuticals raised its 2025 total revenue guidance to a range of US$685 million to US$705 million, including approximately US$75 million to US$85 million from Trokendi XR and Oxtellar XR (Key Developments).

SUPN: Faster Therapy Adoption Will Drive Shares Toward Higher Future Upside

Analysts have raised their price target on Supernus Pharmaceuticals to $65, up from $40, citing a faster than expected ramp for ONAPGO and the potential for additional upside beyond current peak sales assumptions. Analyst Commentary Recent research updates reflect a constructive shift in sentiment toward Supernus, with multiple firms lifting price targets and emphasizing the upside from ONAPGO's adoption curve.

SUPN: Upgrades Will Drive Future Upside As Revenue Outlook Tightens

Analysts have raised their price target on Supernus Pharmaceuticals to $65 from $40, reflecting growing confidence in stronger ONAPGO uptake and expanded long term earnings potential. Analyst Commentary Recent Street research reflects a more constructive stance on Supernus, with higher price targets supported by improving ONAPGO assumptions and a clearer long term earnings trajectory.

SUPN: Upgrades Will Drive Momentum As Earnings Guidance Increases

Analysts have raised their price target for Supernus Pharmaceuticals from $59.33 to $60.50, citing improved revenue growth expectations and increased peak sales forecasts for ONAPGO. Analyst Commentary Recent Street research reflects growing optimism around Supernus Pharmaceuticals, as analysts adjust their targets and ratings in response to strong expectations for ONAPGO and the company’s broader growth trajectory.

SUPN: Upgrades And Revenue Outlook Will Shape Performance Amid Execution Risk

Analysts have raised their price target for Supernus Pharmaceuticals by over $4 to approximately $59.33 per share. This change is due to higher future revenue growth expectations and an improved outlook for key therapies.

Analysts Boost Price Targets for Supernus Pharmaceuticals on Accelerating Growth and Revenue Outlook

Supernus Pharmaceuticals’ analyst price targets have risen sharply, with the fair value estimate increasing from $49.20 to $55.20 per share as analysts cite accelerating growth prospects and higher peak sales potential in key product lines. Analyst Commentary Bullish Takeaways Bullish analysts have raised their price targets substantially, with figures as high as $65 per share.

Widening CNS Access Will Shape Long-term Market Opportunity

Analysts have raised their fair value estimate for Supernus Pharmaceuticals from $40.20 to $49.20, citing a stronger forecast for blockbuster products and higher projected profit margins. This has resulted in a more than $9 increase in their price target.

We Ran A Stock Scan For Earnings Growth And Supernus Pharmaceuticals (NASDAQ:SUPN) Passed With Ease

Sep 10
We Ran A Stock Scan For Earnings Growth And Supernus Pharmaceuticals (NASDAQ:SUPN) Passed With Ease

Benign Growth For Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Underpins Its Share Price

Jul 23
Benign Growth For Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Underpins Its Share Price

Shareholders Can Be Confident That Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings Are High Quality

May 13
Shareholders Can Be Confident That Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings Are High Quality

Investor Optimism Abounds Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) But Growth Is Lacking

Feb 10
Investor Optimism Abounds Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) But Growth Is Lacking

Supernus: New Approval Holds Promise Of Increased Growth

Feb 06

Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth

Nov 12

Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Could Signal Some Risk

Oct 31
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Could Signal Some Risk
User avatar

Qelbree And GOCOVRI Spearhead Robust Revenue Surge, Setting The Path For Market Domination In CNS Therapeutics

Supernus Pharmaceuticals shows robust growth potential with advancements in its product pipeline and significant net sales growth from key products like Qelbree and GOCOVRI.

Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives

Sep 12

Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings

Aug 19
Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings

Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout

Jul 02

Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Apr 24
Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Supernus Pharmaceuticals: Moving Through An 'Inflection Year'

Mar 04

We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

May 10
We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

Feb 03
Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

Opbrengsten en kosten

Hoe Supernus Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGM:SUPN Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
31 Dec 25719-39423106
30 Sep 25682-19380109
30 Jun 2566564352107
31 Mar 2566862344111
31 Dec 2466274336109
30 Sep 246526033523
30 Jun 24630533697
31 Mar 24597-1633795
31 Dec 23608133692
30 Sep 236112632986
30 Jun 236344335983
31 Mar 236685237275
31 Dec 226676137775
30 Sep 226593840578
30 Jun 226305736578
31 Mar 226017333477
31 Dec 215805330590
30 Sep 215648225187
30 Jun 2157110023485
31 Mar 2155611121291
31 Dec 2052012720176
30 Sep 2047712917778
30 Jun 2042411816278
31 Mar 2040211615273
31 Dec 1939311315369
30 Sep 1940810616165
30 Jun 1940910516269
31 Mar 1940410316472
31 Dec 1840911115589
30 Sep 183819915276
30 Jun 183598715268
31 Mar 183357314759
31 Dec 173025713850
30 Sep 172765813347
30 Jun 1725310411842
31 Mar 172289710942
31 Dec 162159110643
30 Sep 161968410139
30 Jun 16179269840
31 Mar 16163189536
31 Dec 15147148929
30 Sep 15135118425
30 Jun 1511857821

Kwaliteitswinsten: SUPN is momenteel verliesgevend.

Groeiende winstmarge: SUPN is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: SUPN is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 34.8% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van SUPN over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: SUPN is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Pharmaceuticals industrie ( -3.3% ).

Rendement op eigen vermogen

Hoge ROE: SUPN heeft een negatief Return on Equity ( -3.63% ), omdat het momenteel verliesgevend is.

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/03 02:17
Aandelenkoers aan het einde van de dag2026/05/01 00:00
Inkomsten2025/12/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Supernus Pharmaceuticals, Inc. wordt gevolgd door 17 analisten. 6 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Emily BodnarBerenberg
Chi Meng FongBofA Global Research
Pavan PatelBofA Global Research